ArticleBJC reports2026
Homologous recombination deficiency (HRD) testing of high-grade serous carcinoma using cytological samples.
Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHomologous recombination deficiency (HRD) is associated with increased sensitivity to PARP inhibitor therapy in various cancer types, including high-grade serous carcinoma (HGSC). Current guidelines recommend HRD testing to guide treatment decisions in HGSG. The majority of HRD assays rely on tumour tissue analysis. The main objective of this study was to assess cytological HGSC samples for HRD testing.
methodsNext generation sequencing using the Oncomine™ Comprehensive Assay Plus (OCAP) panel was performed on 110 matched cytological and histological samples from 55 treatment-naïve HGSC patients to determine the mutational status of 15 homologous recombination repair (HRR)-associated genes including BRCA1/2, and the HRD status based on BRCA1/2 mutational status and genomic instability metric (GIM). Concordance analysis was performed.
resultsCompared to matched histological samples, cytological HGSC samples revealed an overall concordance rate of 89.7% for HRR-associated gene mutations and of 100% for BRCA1/2 mutations, respectively. A moderate correlation between GIM values (Pearson correlation coefficient 0.48), but an overall concordance rate of 90.9% for the HRD status was observed.
conclusionsOur findings demonstrate that cytological HGSC samples can be employed for HRR-associated gene mutation and HRD testing using next generation sequencing with the OCAP panel.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.